Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma.

Blood advances·2026
Same author

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Lancet (London, England)·2026
Same author

Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

British journal of haematology·2026
Same author

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026
Same author

A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities.

Transplantation and cellular therapy·2026
Same author

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

The New England journal of medicine·2026

Related Experiment Video

Updated: May 21, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Lenalidomide in multiple myeloma: Current status and future potential.

Hang Quach1, Anna Kalff, Andrew Spencer

  • 1Myeloma Research Group, Australian Centre for Blood Diseases, Monash University, Clayton, Victoria, Australia. hang.quach@monash.edu

American Journal of Hematology
|May 30, 2012
PubMed
Summary

Lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs) revolutionizing multiple myeloma (MM) treatment. Further research into lenalidomide

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: May 21, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Immunomodulatory drugs (IMiDs) like lenalidomide and pomalidomide have transformed multiple myeloma (MM) therapy.
  • Understanding disease biology has enabled the development of targeted MM treatments.
  • Lenalidomide's full therapeutic potential in MM remains to be explored.

Purpose of the Study:

  • To review the biological effects of lenalidomide in multiple myeloma.
  • To summarize clinical certainties and uncertainties regarding lenalidomide use in MM.
  • To explore the future potential of lenalidomide in combination therapies for MM.

Main Methods:

  • Literature review of lenalidomide's biological effects.
  • Analysis of clinical trial data and real-world evidence for lenalidomide in MM.
  • Exploration of potential synergistic combinations with other therapeutic agents.

Main Results:

  • Lenalidomide exhibits diverse biological effects contributing to its efficacy in MM.
  • Established clinical benefits of lenalidomide in various MM settings.
  • Identified areas of uncertainty and ongoing research in lenalidomide treatment.

Conclusions:

  • Lenalidomide is a cornerstone therapy for multiple myeloma.
  • Further research is needed to fully elucidate lenalidomide's mechanisms and optimize its use.
  • Combination strategies hold promise for enhancing lenalidomide's impact in MM treatment.